Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk
Status:
Completed
Trial end date:
2019-11-26
Target enrollment:
Participant gender:
Summary
Investigators recently demonstrated that coronary flow reserve (CFR) significantly improved
after rosuvastatin therapy in hypertensive patients with average levels of serum cholesterol
by measuring the change in CFR after 1 year treatment with rosuvastatin in the RESERVE
(Rosuvastatin Effect on Coronary Flow Reserve in Hypertensive Patients) I trial. However, the
absence of a placebo group made it difficult to exclude the possibility that lifestyle
modification and antihypertensive medication also played a role in improving CFR in our
previous study. In a double-blind, randomized trial, investigators try to examine the
hypothesis that rosuvastatin added to lifestyle modification will be superior to lifestyle
modification alone in improving CFR in hypertensive patients .